In addition, the results of the control group suggest that patients started treatment soon after the diagnosis of advanced NSCLC (with negative PD-L1), with a span of 14 days, with a good LIPI, but due to the poor efficacy of the chemotherapy, they had a rapid progression and started the second-line oncological treatment within 6 months. This evidence concerns the gene CD274 and non-small cell lung carcinoma.